How Recent Developments Are Changing the Theravance Biopharma Investment Story [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
This change reflects growing confidence in the company's strategic direction and recent positive developments, such as the monetization of key assets and new international opportunities. Stay tuned to discover how you can stay informed about evolving analyst perspectives and the ongoing narrative for Theravance Biopharma. What Wall Street Has Been Saying Analysts have recently provided updated viewpoints on Theravance Biopharma, balancing optimism for the company's ongoing execution and future prospects with notes of caution around valuation and near-term factors. The latest commentary reflects both strong bullish conviction and more measured, risk-aware perspectives following key corporate developments. ?? Bullish Takeaways The monetization of the non-core asset Trelegy continues to be seen as a pivotal move that has strengthened Theravance's balance sheet and provided the flexibility to pursue new strategic initiatives. Approval of Yupelri in China, triggering a $7.5 milli
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.MarketBeat
- Theravance Biopharma (NASDAQ:TBPH) had its price target raised by analysts at BTIG Research from $25.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TBPH&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025PR Newswire
TBPH
Earnings
- 11/10/25 - Beat
TBPH
Sec Filings
- 12/3/25 - Form 144
- 12/1/25 - Form 4
- 11/26/25 - Form 144
- TBPH's page on the SEC website